Fig. 3: DC-based cancer therapy strategies.

Current dendritic cell (DC)-based cancer immunotherapeutic strategies include DC vaccines, either alone or in combination with immune checkpoint blockade (ICB), adoptive cell transfer (ACT), and conventional therapies. In parallel, platforms and adjuvants targeting endogenous DCs have shown significant potential in enhancing antitumor immunity. Furthermore, strategies aimed at reversing the immunosuppressive tumor microenvironment can improve the efficacy of DC-based immunotherapies. PLG: poly-lactide-co-glycolide. Created with BioRender.com.